Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04592029

TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Hepatocellular Carcinoma Non-resectable Clinical Trial

Official title:
Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced Hepatocellular Carcinoma: A Prospective Study

Clinical Trial Summary

This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).

Clinical Trial Description

This is a Phase Ib study to evaluate the safety and efficacy of TACE combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced HCC. 36-39 subjects with unresectable intermediate or advanced HCC will be enrolled in the study. This study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety evaluation. Then, sintilimab 200mg/kg IV. every three weeks (q3w) + the select specific dose of bevacizumab 7.5mg/kg (group 1) or 15mg/kg (group2) IV q3w, expand to 36 patients (18 patients each group) for the further safety and efficacy study. Sintilimab and bevacizumab will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated based on the evaluation of follow-up laboratory and imaging examination. And the study treatment of sintilimab and bevacizumab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04592029
Study type Interventional
Source Second Affiliated Hospital of Guangzhou Medical University
Contact
Status Active, not recruiting
Phase Phase 1
Start date September 27, 2020
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Not yet recruiting NCT03283956 - Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan N/A
Recruiting NCT03652467 - The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma Phase 1
Recruiting NCT05031949 - Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma Phase 1
Completed NCT03533920 - Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma N/A
Recruiting NCT05992220 - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion Phase 2
Not yet recruiting NCT05057104 - Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
Completed NCT04599777 - TACE Combined With Sorafenib and Tislelizumab for Advanced HCC Phase 2
Completed NCT04599790 - TACE Combined With Lenvatinib and Sintilimab for Advanced HCC Phase 2
Recruiting NCT02967887 - Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC Phase 2
Recruiting NCT05608213 - Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC Phase 3
Recruiting NCT05608200 - Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC Phase 3
Completed NCT04926376 - Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC N/A
Recruiting NCT06133062 - Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma Phase 2
Completed NCT02989922 - A Study to Evaluate SHR-1210 in Subjects With Advanced HCC Phase 2
Recruiting NCT04273100 - PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC Phase 2
Completed NCT06408753 - Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
Withdrawn NCT03563170 - QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Phase 1/Phase 2
Recruiting NCT05390112 - Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Recruiting NCT05713994 - Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma